Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Shares (Diluted, Weighted) for the quarter ending September 30, 2023: 50,030,759.00

Icosavax Inc Shares (Diluted, Weighted) is 50,030,759.00 for the quarter ending September 30, 2023, a 25.87% change year over year. Shares (Diluted, Weighted) represent the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Icosavax Inc Shares (Diluted, Weighted) for the quarter ending September 30, 2022 was 39,748,984.00, a 50.02% change year over year.
Icosavax Inc Shares (Diluted, Weighted) for the quarter ending September 30, 2021 was 26,494,914.00, a 787.55% change year over year.
Icosavax Inc Shares (Diluted, Weighted) for the quarter ending September 30, 2020 was 2,985,183.00.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends